Results 21 to 30 of about 13,925,210 (307)

Second-line anti-tuberculosis drug resistance testing in Ghana identifies the first extensively drug-resistant tuberculosis case [PDF]

, 2018
Background: Drug resistance surveillance is crucial for tuberculosis (TB) control. Therefore, our goal was to determine the prevalence of second-line anti-TB drug resistance among diverse primary drug-resistant Mycobacterium tuberculosis complex (MTBC ...
Forson, Audrey, Martin Antonio, Yeboah-Manu, Dorothy, Michael Amo Omari, Adwoa Asante-Poku, Audrey Forson, Jacob Otu, Isaac Darko Otchere, Osei-Wusu, Stephen, Darko Otchere, Isaac, Amo Omari, Michael, Dorothy Yeboah-Manu, Otu, Jacob, Stephen Osei-Wusu, Asante-Poku, Adwoa, Prince Asare, Asare, Prince, Antonio, Martin, Amo Omari M, Asante-Poku A, Asare P, Osei-Wusu S, Forson A, Antonio M, Yeboah-Manu D, Otu J, Darko Otchere I   +26 more
core   +2 more sources

Low-level viraemia despite emergence of dolutegravir-resistant variants

Southern African Journal of HIV Medicine, 2022
No abstract available.
Johannes C. Botha, Kim Steegen, Mariam Edoo, Jeremy Nel, Gert U. van Zyl   +4 more
doaj   +1 more source

Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. [PDF]

, 2009
In high-income countries, viral load is routinely measured to detect failure of antiretroviral therapy (ART) and guide switching to second-line ART. Viral load monitoring is not generally available in resource-limited settings. We examined switching from
Sprinz, Eduardo, Egger, Matthias, Wood, R, Tuboi, Suely, Kumarasamy, N, Braitstein, Paula, Kumarasamy, Nagalingeswaran, Schecter, Mauro, Nash, D, Calmy, Alexandra, Brinkhof, Martin W G, Jahn, Andreas, Schechter, M, Boulle, A, Calmy, A, Brinkhof, Martin, Dabis, F, Tweya, Hannock, Brinkhof, Martin, W.G., Keiser, Olivia, MacPhail, Patrick, MacPhail, P, Pujades-Rodriguez, Mar, Tuboi, S, Schechter, Mauro, Nash, Denis, Jahn, A, Braitstein, P, Boulle, Andrew, Dabis, François, Lüthy, R, Keiser, O, Lüthy, Ruedi, Sprinz, E, Tweya, H, Wood, Robin, Pujades-Rodriguez, M, ART-LINC of IeDEA Study Group, Calmy A, Schecter M, Tuboi S, Nash D, Jahn A, Tweya H, Boulle A, Lüthy R, Kumarasamy N, Keiser O, MacPhail P, Egger M, Brinkhof MW, Sprinz E, Pujades-Rodriguez M, Braitstein P, Dabis F, Wood R   +55 more
core   +2 more sources

Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting for Large B-cell Lymphoma: A Game Changer?

Hematology/Oncology and Stem Cell Therapy, 2022
Chimeric antigen receptor T-cell (CAR T) therapy has been proven effective in the third-line (and beyond) setting in patients with large B-cell lymphoma (LBCL).
Razan Mohty, Muhamad Alhaj Moustafa, Mahmoud Aljurf, Hemant Murthy, Mohamed A. Kharfan-Dabaja   +4 more
doaj   +1 more source

Combination of Second-line Antirheumatic Drugs

Annals of Medicine, 1997
Single drug therapy is often not satisfactory in the treatment of chronic arthritis. The combination of second-line antirheumatic drugs is therefore increasingly employed. Various strategies of combining drugs can be used, starting with combinations or adding agents in case of insufficient effect of single therapy.
Haagsma, C.J., Riel, P.L.C.M. van
openaire   +4 more sources

Second-Line Therapy for Advanced NSCLC [PDF]

The Oncologist, 2013
Abstract Most patients with lung cancer have non-small cell lung cancer (NSCLC) subtype and have advanced disease at the time of diagnosis. Improvements in both first-line and subsequent therapies are allowing longer survival and enhanced quality of life for these patients.
Jared M, Weiss, Thomas E, Stinchcombe
openaire   +2 more sources

Clinical audit of current Helicobacter pylori treatment outcomes in Singapore

Singapore Medical Journal, 2022
Introduction: H. pylori eradication reduces the risk of gastric malignancies and peptic ulcer disease. First-line therapies include 14-day PAC (proton pump inhibitor [PPI], amoxicillin, clarithromycin) and PBMT (PPI, bismuth, metronidazole, tetracycline).
Tiing Leong Ang, Kim Wei Lim, Daphne Ang, Yu Jun Wong, Malcolm Tan, Andrew Siang Yih Wong   +5 more
doaj   +1 more source

Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration [PDF]

, 2011
Article approval pendingWith expanding pediatric antiretroviral therapy (ART) access, children will begin to experience treatment failure and require second-line therapy. We evaluated the probability and determinants of virologic failure and switching in
Technau K., Olivia Keiser, Rabie, Helena, Giddy, Janet, Egger, Matthias, Davies M.-A., Eley, Brian, Van Cutsem, Gilles, Harry Moultrie, Janet Giddy, Karl Technau, Moultrie H., Helena Rabie, Eley B., Giddy J., Egger M., Robin Wood, Technau, Karl, Rabie H., Van Cutsem G., Gilles Van Cutsem, Matthias Egger, Keiser, Olivia, Brian Eley, Moultrie, Harry, Boulle, Andrew, Mary-Ann Davies, Davies, Mary-Ann, Andrew Boulle, Boulle A., Keiser O., Wood R., Wood, Robin   +32 more
core   +3 more sources

Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA trial

Медицинский совет, 2020
Background. Ramucirumab is a monoclonal antibody that inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). The study is aimed to analyse prognostic factors for survival in patients with disseminated gastric cancer who received ramucirumab
N. S. Besova, T. A. Titova, Е. V. Artamonova, A. A. Tryakin, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukalchuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, I. S. Stilidi   +19 more
doaj   +1 more source

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda. [PDF]

, 2014
We investigated phenotypic and genotypic resistance after 2 years of first-line therapy with two HIV treatment regimens in the absence of virological ...
Awio, P., Munderi, P., Pillay, D., Ndembi, N., Nkurunziza, P., Ndembi, N, Pattery, T, Dunn, DT, van Cauwenberge, A, Gilks, C. F., Gilks, CF, Awio, P, Munderi, P, Nkurunziza, P, Kaleebu, P., Pillay, D, Goodall, RL, DART Virology Group and Trial Teams, Kaleebu, P, Goodall, R. L., Kityo, C., Dunn, D. T., Kityo, C, Pattery, T., van Cauwenberge, A., K. Mataruka, B. Kikaire, M. Nabankkema, H. Grosskurth, P. Khauka, M. Namyalo, C. Kityo, C. Parry, C. F. Gilks, M. Spyer, R. Magala, P. Kaleebu, R. L. Goodall, P. Nkurunziza, N. Ndembi, R. Goodall, A. Zalwango, T. Pattery, L. Generous, P. Awio, D. Dunn, D. Pillay, K. Fadhiru, G. Kabuye, L. Mugarura, G. Nassuna, M. Chirara, M. Katuramur, B. Magambo, J. Nkalubo, R. Massa, A. van Cauwenberge, E. Zalwango, V. Robertson, P. Munderi, D. Yirrell, R. Kasirye, D. M. Gibb, A. Kapaata, D. T. Dunn, D. Nsibambi, F. Lyagoba, T. Musunga, A.L. McCormick, M. Nakazibwe, C. Gilks   +70 more
core   +1 more source